Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates

Advanced Drug Delivery Reviews

Volumn 55, Issue 10, 2003, Pages 1261-1277

  Caliceti, Paolo ^a   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biodistribution; PEG; Pharmacokinetic; Protein conjugates

Indexed keywords

BIOLOGICAL ORGANS; CELLS; COMPOSITION; IMMUNOLOGY; MOLECULAR WEIGHT; PHARMACOKINETICS; PHYSIOLOGY; POLYETHYLENE GLYCOLS; TISSUE; ULTRAFILTRATION;

GLYCOSYLATION; PERMEATION; PHAGOCYTOSIS;

PROTEINS;

ADENOSINE DEAMINASE; ALLERGEN; AMINE; ASPARAGINASE MACROGOL; BETA GLUCURONIDASE; CARBOXYL GROUP; MACROGOL DERIVATIVE; OVALBUMIN; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 2; RECOMBINANT RECEPTOR; STAPHYLOKINASE; SUPEROXIDE DISMUTASE MACROGOL; TUMOR NECROSIS FACTOR RECEPTOR 1; URATE OXIDASE;

ANTIBODY PRODUCTION; ANTIGENICITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PENETRATION; DRUG RETENTION; ELECTRIC POTENTIAL; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; LIVER CELL; LIVER CLEARANCE; LYMPH NODE; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RETICULOENDOTHELIAL SYSTEM; REVIEW; TISSUE DISTRIBUTION;

EID: 0344420226     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00108-X     Document Type: Article

References (73)

1. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;Mercel Dekker, New York.
2. Kompella U.B., Lee V.H.L. Pharmacokinetics of peptide and protein drugs. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;391 Marcel Dekker, New York.
3. Rabkin R., Dahl D.C. Renal uptake and disposal of proteins and peptides. Audus K.L., Raub T.J. Biological Barriers in Protein Delivery. 1993;299 Plenum Press, New York.
4. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:2000;539-551.
5. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;249-304.
6. Kartre K. The conjugation of proteins with poly(ethylene glycol) and other polymers. Adv. Drug Deliv. Rev. 10:1993;91-114.
7. Brenner B.M., Hostetter T.H., Humes H.D. Glomerular permeselectivity: barrier function based on discrimination of molecular size and charge. Am. J. Physiol. 234:1978;F455-F460.
8. Deen W.M., Bohrer M.P., Brenner B.M. Macromolecule transport across glomerular capillaries: application of pore theory. Kidney Int. 16:1979;353-365.
9. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:2001;405-417.
10. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition of macromolecules in tumor bearing mice. Pharm. Res. 7:1990;339-346.
11. Knauff M.J., Bell D.P., Hirtzer P., Luo Z.P., Young J.D., Kartre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers. J. Biol. Chem. 263:1988;15064-15070.
12. Milton Harris J. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. 1991;Plenum Press, New York.
13. Sherman M.R., Williams L.D., Saifer M.C.P., French J.A., Kwak L.W., Oppenheim J.J. Conjugation of high, molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony stimulating factors as model substrates. Harrris J.M., Zalipsky S. Poly(Ethylene Glycol): Chemistry and Biological Applications. 1997;155 ACS, Washington, DC.
14. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.
15. Yamaoka T., Tabata Y., Ikada Y. Fate of water-soluble polymers administered via different routes. J. Pharm. Sci. 84:1995;349-354.
16. Nakaoka R., Tabata Y., Yamaoka T., Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J. Control. Release. 46:1997;253-262.
17. W.J. Arendshorst, L.G. Navar, Renal circulation and glomerular hemodynamics, in: R.W. Schrier, C.W. Gottshalk (Eds.), Diseases of the Kidney, Little, Brown, Boston, MA, 1988, p. 65.
18. Conover C.D., Gilbert C.W., Shum K.L., Shorr R.L. The impact of polyethylene glycol conjugation on bovine hemoglobin's circulatory half-life and renal effects in a rabbit top-loaded transfusion model. Artif. Organs. 21:1997;907-915.
19. Clark R., Olson K., Fuh G., Marian M., Mortensen D., Teshima G., Chang S., Chu H., Mukku V., Canova-Davis E., Sommers T., Cronin M., Winkler M., Wells J.A. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271:1996;21969-21977.
20. Saifer M.G.P., Williams L.D., Sherman M.R., French J.A., Kwak L.W., Oppenheim J.J. Improved conjugation of cytokines using high molecular weight poly(ethylene glycol): PEG-GM-CSF as prototype. Polym. Preprints. 38:1997;576-577.
21. Gaertner H.F., Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 7:1996;38-44.
22. Wang Y.S., Youngster S., Bausch J., Zhang R., Mc Nemar C., Wyss D.F. Identification of the mayor positional isomer of pegylated interferon alpha-2b. Biochemistry. 39:2000;10634-10640.
23. Tsutsumi Y., Tsunoda S., Kamada H., Kihira T., Nagakawa S., Kaneda Y., Kanamori T., Mayumi T. Molecular design of hybrid tumor necrosis factor II: the molecular size of polyethylene glycol-modified tumor necrosis factor affects its antitumor potency. Br. J. Cancer. 74:1996;1090-1095.
24. Lee K.C., Tak K.K., Park M.O., Lee J.T., Na D.H., Yoo S.D., Lee H.S., DeLuca P.P. Preparation and characterization of polyethylene-glycol-modified salmon calictonins. Pharm. Dev. Technol. 4:1999;269.
25. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Enrich G.K., Pan W., Xu Z.X., Modi M.W., Farod A., Berthold W. Rational design of a potent, long lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-2a for the treatment of hepatitis C. Bioconjug. Chem. 12:2001;195-202.
26. Koumenis I., Sshahrokh Z., Leong S., Hsei V., Deforge L., Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)2 by amine-specific PEGylation with preserved bioactivity. Int. J. Pharm. 198:2000;83-95.
27. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17:1999;780-783.
28. Lee L.S., Connover C., Shi C., Whiltlow M., Fipula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug. Chem. 10:1999;973-981.
29. Renkin E.M., Gilmore J.P. Orloff J., Berliner R.W. Renal Physiology. 1973;185-248 American Physiological Society, Bethesda, MD.
30. Edwards C.K. PEGylated recombinant human soluble tumor necrosis factor receptor type I (r-Hu-sTNF-RI) novel high affinity TNF receptor designed for chronic inflammatory disease. Ann. Rheum. Dis. 58:1999;173-181.
31. Friman S., Egestad B., Sjövall J., Svanvik J. Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. J. Hepatol. 17:1993;48-55.
32. Beranová M., Wasserbauer R., Vanèurová D., Štifter M., Ocenášková J., Mára M. Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. Biomaterials. 11:1990.
33. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 3:(1):2000;125-136.
34. Herold D.A., Keil K., Bruns D.E. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem. Pharmacol. 38:(1):1989;73-76.
35. Seongok H., Chongyoup K., Kwon D. Thermal/oxidative degradation and stabilization of polyethylene glycol. Polymer. 38:1997;317-323.
36. ®) is primarily hepatic. Hepatol. 32:2000;371A.
37. Kartre N.V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144:1990;209-213.
38. Abuchowski A.A., van Es T., C Palczuk N., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252:1977;3578-3581.
39. Davis F.F., Kazo G.M., Nucci M.L., Abuchowski A. Reduction of immunogenicity and extension of circulating half-life of peptides and proteins. Lee V.H.L. Peptide and Protein Drug Delivery. 1991;831 Mercel Dekker, New York.
40. Sehon A.H. Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol). Adv. Drug Deliv. Rev. 6:1991;203-217.
41. Caliceti P., Veronese F.M., Jonak Z. Immunogenic and tolerogenic properties of monomethoxypoly(ethylene glycol) conjugated proteins. Farmaco. 54:1999;430-437.
42. Richter A.W., Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70:1983;124-131.
43. Richter A.W., Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and healthy blood donors. Int. Arch. Allergy Appl. Immunol. 74:1984;36-39.
44. Tsuji J.-C., Hirose K. Studies on antigenicity of polyethylene glycol (PEG)-modified uricase. Int. J. Immunopharmacol. 7:1985;725-730.
45. Caliceti P., Schiavon O., Veronese F.M. Immunological properties of usricase conjugated to neutral soluble polymers. Bioconjug. Chem. 12:2001;515-522.
46. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54:2002;531-545.
47. Veronese F.M., Monfardini C., Caliceti P., Schiavon O., Scrawen M.D., Beer D. Improvement of pharmacokinetic, immunological and stability properties of asparginase by conjugation of linear and branched monomethoxy poly(ethylene glycol). J. Control. Release. 40:1966;199-209.
48. Cheng T.L., Wu P.Y., Wu M.F., Chern J.W., Roffler S.R. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 10:1999;520-528.
49. Cheng T.L., Cheng B.M., W Chern J., Wu M.F., Roffler S.R. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug. Chem. 11:2000;258-266.
50. Wanwetswinkel S., Plaisance S., Zhi-yong Z., Vanlinthout I., Brepoeles K., Lasters I., Collen D., Jespers L. Pharmacokinetic and thromolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood. 95:2000;936-942.
51. Francis G.E., Fisher D., Delgado C., Malik F., Gardiner A., Neale D. Pegylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. Int. J. Hematol. 68:1998;1-18.
52. Yamaoka T., Tabata Y., Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous injection. J. Pharm. Pharmacol. 47:1995;479-486.
53. Yabe Y., Nishikawa M., Tamada A., Takakura Y., Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase. J. Pharmacol. Exp. Ther. 289:1999;1176-1184.
54. Caliceti P., Schiavon O., Veronese F.M. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjug. Chem. 10:1999;638-646.
55. Lamka J., Schiavon O., Laznicek M., Caliceti P., M Veronese F. Distribution of catalase, ribonuclease, superoxide dismutase modified by monomethoxy(polyethylene glycol) into rat cerebral lymph and lymphatic nodes. Physiol. Res. 44:1995;307-313.
56. Chen S.A., Sawchuk R.J., Brundage R.C., Horvath C., Mendenhall H.V., Gunther R.A., Braeckman R.A. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J. Pharmacol. Exp. Ther. 293:2000;248-259.
57. Xie D., Hale V.G. Factors affecting the lymphatic absorption of macromolecules following extravascular administration. Pharm. Res. 13:1996;S-396.
58. Kataoka K. Targetable polymeric drugs. Park K. Controlled Drug Delivery Challenges and Strategies. 1997;49 American Chemical Society.
59. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer. 31:1995;766-770.
60. Sawa T., Wu J., Akaike T., Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 60:2000;666-671.
61. Tan Y., Sun X., Xu M., An Z., Tan X., Han Q., Miljkovich D.A., Yung M.R., Hoffman M. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr. Purif. 12:1998;45-52.
62. Cheng T.L., Chen B.M., Chan L.Y., Wu P.Y., Chern J.W., Roffler S.R. Poly(ethylene glycol) modification of b-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol. Immunother. 44:1997;305-315.
63. Deckert P.M., Jungbluth A., Montalto N., Clark M.A., Finn R.D., Williams C., Righards E.C., Panageas K.S., Old L.J., Welt S. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Int. J. Cancer. 87:2000;832-839.
64. Delgado C., Pedley R.B., Herraz A., Boden R., Boden J.A., Keep P.A., Chester K.A., Fisher D., Begent R.H.J., Francis G.E. Enhanced tumor specificity of an anti-carcinoembrionic antigen Fab′ fragment by poly(ethylene glycol) (PEG) modification. Br. J. Cancer. 73:1996;175-182.
65. Francis G.E., Delgado C., Fisher D., Malik F., Agrawal A.K. Polyethylene glycol modification: relevance of improved methodology to tumor targeting. J. Drug Target. 3:1996;321-340.
66. Jain R.K. Physiological barriers to delivery monoclonal antibodies and other macromolecules to tumors. Cancer Res. 50:1990;814s-819.
67. Hurwitz E., Klapper L.N., Wilchek M., Yarden Y., Sela M. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol. Immunother. 49:2000;226-234.
68. Takashina K., Kitamura K., Yamaguchi T., Noguchi A., Noguchi A., Tsurumi H. Comparative pharmacokinetic properties of murine monoclonal antibodies A7 modified with neocarzinostatin, dextran and polyethylene glycol. Jpn. J. Cancer Res. 82:1991;1145-1150.
69. Kitamura K., Takahashi T., Yamaguchi T., Noguchi A., Noguchi A., Takashina K., Tsurumi H., Inagake M., Toyokuni T., Hakamori S. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 51:1991;4310-4315.
70. Monfardini C., Veronese F.M. Stabilization of substances in circulation. Bioconjug. Chem. 9:1998;418-450.
71. Fuertges F., Abuchoswski A. The clinical efficacy of polyethylene glycol)-modified proteins. J. Control. Release. 11:1990;139-148.
72. Veronese F.M., Caliceti P., Pastorino A., Schiavon O., Sartore L., Banci L., Monsu Scolaro L. Preparation, physico-chemical and pharmacokinetic characterization of monomethoxypoly(ethylene glycol)-derivatized superoxide dismutase. J. Control. Release. 10:1989;145-154.
73. Jensen-Pippo K.E., Whitcomb K.L., DePrince R.B., Ralph L., Habberfield A.D. Pharm. Res. 13:1996;102-107.